Resistance of cancer cells to immune recognition and killing

Medical Hypotheses

Volumn 54, Issue 3, 2000, Pages 456-460

  Lipinski, B ^a   Egyud, L G ^a  

^a Cell Research Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; HUMAN SERUM ALBUMIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER; CELL SURFACE; FIBRINOLYSIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NATURAL KILLER CELL; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0034127606     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0876     Document Type: Article

References (48)

1. Polednak A. B. Estimating the Prevalence of Cancer in the United States. Cancer. 80:1997;136-141.
2. Lloyd K. O. Tumor antigens known to be immunogen in man. Specific immunotherapy of cancer with vaccines. Ann N Y Acad Sci. 690:1993;51-58.
3. Gorski A., Castronovo V., Stepien-Olszewska B. Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactions. Cell Adhes Communic. 2:1994;225-233.
4. Cernak I., Jevremovic M., Vasiljevska M., Jovanovic M., Malicevic Z. The possible mechanism of benefit effects of the mature thymic calf extracts (THYMEX-L) in mice bearing a transplanted melanoma. Interntl J Thymology. 4:1996;355-361.
5. Mukherjee A. B., Laki K., Agarwal A. K. Possible mechanism of success and allotransplantation in nature: mammalian pregnancy. Med Hypotheses. 6:1980;1043-1051.
6. Lipinski B., Nowak A., Gurewich V. Fibrinolysis versus fibrinogenolysis of man: resistance of fibrinogen to breakdown by fibrinolytic activity induced by venous occlusion. Experientia. 30:1974;84-85.
7. Mannick M., Person R. E. Immunoglobulin G and serum albumin isolated from the articular cartilage of patients with rheumatoid arthritis contains covalent heteropolymers with proteoglycans. Rheumatol Int. 13:1993;121-129.
8. Lipinski B. In vitro preparation and partial characterization of a novel complex of human fibrinogen with albumin. J Protein Chem. 14:1959;259-262.
9. Lipinski B. Hydrophobic interactions in plasma proteins and pathogenesis of atherosclerosis. Atherosclerosis. 115:1995;S123.
10. Lipinski B. Bioelectric theory of pathogenesis of atherosclerosis. J Bioelectricity. 3:1984;177-183.
11. Lipinski B. Effect of thiol-induced disulfide exchange on plasma clotting and fibrinolysis. Thromb Haemost. 69:1993;1260.
12. Lipinski B., Federman S. M., Krolewski A. S. Plasma macromolecular protein complex: interaction with fibrin and fibrinolysis. Thromb Res. 78:1995;461-465.
13. Lipinski B. Aurin tricarboxylic acid inhibits fibrinogen clotting by forming soluble fibrin complexes. Thromb Res. 77:1995;379-380.
14. Lipinski B. Suramin inhibits thrombin induced fibrinogen clotting by forming soluble fibrin complexes. Thromb Haemost. 73:1995;985.
15. Lipinski B., Federman S. M., Krolewski A. S. Comments on plasma fibrinogen levels by functional methods. Thromb Haemost. 72:1994;985-989.
16. Dvorak H. F., Senger D. R., Dvorak A. M. Fibrin as a component of the tumor stroma: origins and biological significance. Cancer Metastasis Rev. 2:1983;41-73.
17. Bardos H., Molnar P., Csecsei G., Adany R. Fibrin deposition in primary and metastatic human brain tumors. Blood Coagul Fibrinolysis. 7:1996;536-548.
18. Wojtukiewicz M. Z., Zacharaski L. R., Memoli V. A. Fibrinogen-fibrin transformation in situ in renal cell carcinoma. Anticancer Res. 10:1990;579-582.
19. Gordon S. G., Franks J., Lewis B. Cancer procoagulant: a factor X activating procoagulant from malignant tissue. Thromb Res. 6:1975;126-137.
20. Dano K., Andreasen P. A., Grondahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degeneration and cancer. Adv Cancer Res. 44:1985;139-266.
21. Kwaan H. C., Keer H. M. Fibrinolysis and Cancer. Semin Thromb Haemost. 16:1990;230-235.
22. Kondera-Anasz Z., Gisman K., Mertas A. Selected parameters of coagulation, fibrinolysis and antibodies to fibrinogen in lung cancer. Pneumonol Alergol Pol. 61:1993;61-466.
23. Egyud L. G., Lipinski B. Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer. Med Hypotheses. 36:1991;336-340.
24. Lipinski B., Egyud L. G. Thiol-induced crosslinking of human blood proteins. Medic Chem Lett. 2:1991;919-924.
25. Soreide J. A., Lea O. A., Kvinnsland S. Cytosol albumin content in operable breast cancer. Acta Oncolog. 30:1991;797-802.
26. Etzrodt A., Bigalke L. H., Jung H., Tolxdorf T. Occurrence and distribution of plasma proteins in malignant and benign breast tissue. Tumor Diagn Ther. 4:1993;109-113.
27. Germain P., Habrioux G. Modulation of estradiol mitogenic effect on human breast cancer cells by serum albumin. Anticancer Res. 13:1993;1581-1586.
28. Trojan J., Uriel J. Immunocytochemical localization of alphafetoprotein (AFP) and serum albumin in dermal tissue derivatives. Oncodev Biol Med. 3:1982;12-22.
29. Vercelli-Retta J., Manana G., Almeida E., Chiribao C., Estvez A., Moro R. Normal serum proteins in female breast carcinomas. Ann Pathol. 7:1987;209-215.
30. Fleck A., Raines G., Hawker F., Trotter J., Wallace P. I. Increased vascular permeability: a major cause of hypoalbuminemia in disease and injury. Lancet. i:1985;781-784.
31. Rockwell W. B., Ehrlich H. P. Fibrinolysis inhibition in human burn blister fluid. J Burn Care Rehabil. 11:1990;1-6.
32. Dvorak H. F. Tumors: wounds that do not heal. N Engl J Med. 315:1986;1650-1659.
33. Kaufman P., Huppertz B., Frank H. G. The fibrinoids of human placenta: origin, composition and functional relevance. Ann Anat. 178:1996;485-501.
34. Uszynski M. Isolation of peptides with anti-urokinase activity from the human placenta. Thrombos Haemost. 42:1980;1411-1416.
35. Brzosko W., Nowoslaswski A., Pisarski T. Analiza immunochemiczna mas wloknikowatych w lozysku ludzkim. [Immunochemical analysis of fibrin masses in human placenta]. Ginekol Pol. 34:1965;121-130.
36. White M. W. The reducing conditions of cancerous tissue and its apparent significance. Abdom Surg. 15:1973;211-221.
37. Benedetto C., Bajardi F., Ghiringhello B., Mazozio L., Nohamer G. Quantitative measurements of the changes in thiols in cervical neoplasia and carcinoma of the human uterine cervix provide evidence for the existence of a biochemical field effect. Cancer Res. 50:1990;6663-6667.
38. Pardoll D. P. New strategies for enhancing the immunogenicity of tumors. Curr Opinion Immunol. 5:1993;719-725.
39. Houghton A. N. Cancer antigens: immune recognition of self and altered self. J Exp Med. 180:1994;1-4.
40. Maizels R. M., Phillipp M., Dasgupta A., Partoni F. Human serum albumin is a major component on the surface of microfilariae of Wuchereria bancrofti. Parasite Immunol. 6:1984;185-190.
41. Wieman B., Starnes C. O. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmac Ther. 64:1994;529-564.
42. Kirchner H. H., Anton P., Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol. 13:1995;171-173.
43. Moore A. E. Effect of viruses on tumors. Annu Rev Microbiol. 1995;393-410.
44. Southam C. M. Present status of oncolytic virus studies. Trans NY Acad Sci. 22:1960;687-693.
45. Csatary L. I. Viruses in the treatment of cancer. Lancet. 2:1971;825.
46. Dohlsten M., Abrahmsen L., Bjork P. Monoclonal antibody-superantigen fusion proteins. Proc Natl Acad Sci USA. 91:1994;8945-8948.
47. Dohlsten M., Lando P. A., Bjork P. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother. 41:1995;162-168.
48. Cassel W. A., Garrett R. E. Newcastle disease virus as an antineoplastic agent. Cancer. 18:1995;863-868.